康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09966 康宁杰瑞制药-B

已收盘 11-12 16:08:06

5.945

-0.205

-3.33%

最高6.190	最低5.755	成交量96.10万
今开6.030	昨收6.150	日振幅7.07%
总市值57.37亿	流通市值57.37亿	总股本9.65亿
成交额569.20万	换手率0.10%	流通股本9.65亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":5.945,"timestamp":1794470886010,"preClose":6.15,"halted":0,"volume":961000,"delay":0,"changeRate":-0.03333333333333334,"floatShares":965000000,"shares":965000000,"eps":-0.12,"marketStatus":"已收盘","change":-0.205,"latestTime":"11-12 16:08:06","open":6.03,"high":6.19,"low":5.755,"amount":5691970,"amplitude":0.070732,"askPrice":5.95,"askSize":2000,"bidPrice":5.845,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.210595,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":5,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":6.15,"openAndCloseTimeList":[[1794447000000,1794456000000],[1794459600000,1794470400000]],"volumeRatio":1.395585,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"1114830991","title":"康宁杰瑞制药-B委任吴嘉俊为首席财务官 王飞因工作安排辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1114830991","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114830991?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:05","pubTimestamp":1794441929,"startTime":"0","endTime":"0","summary":"2026年11月12日，康宁杰瑞制药-B发布自愿公告称，董事会已委任吴嘉俊为公司首席财务官，负责集团的资本市场策略、投资者关系管理及行业竞争分析。原首席财务官王飞因其他工作安排辞任，双方不存在意见分歧。公告披露，吴嘉俊在资本市场、证券研究、投资者关系及投融资管理领域拥有丰富经验。康宁杰瑞制药-B董事长兼执行董事徐霆博士代表董事会对王飞的贡献表示感谢，并欢迎吴嘉俊履新。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682355495","title":"康宁杰瑞制药-B(09966.HK)：吴嘉俊获委任为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2682355495","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682355495?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:03","pubTimestamp":1794441820,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682535144","title":"康宁杰瑞制药－Ｂ：委任吴嘉俊为首席财务官 王飞辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2682535144","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682535144?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:02","pubTimestamp":1794441720,"startTime":"0","endTime":"0","summary":"21财经11月12日电，康宁杰瑞制药－Ｂ（09966.HK）发布自愿公告，公司董事会宣布，委任吴嘉俊先生为首席财务官，主要负责集团的资本市场策略、投资者关系管理及行业竞争分析。吴嘉俊在资本市场、证券研究及投融资管理等方面拥有丰富经验。同时，王飞先生因其他工作安排辞任首席财务官，已确认与公司无意见分歧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611123929061138.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611123929061138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146089019","title":"康宁杰瑞制药-B：11月11日回购23.9万股股份，涉资约146.99万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146089019","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146089019?lang=zh_cn&edition=full","pubTime":"2026-11-11 19:01","pubTimestamp":1794394872,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年11月11日发布公告称，当日于香港联交所场内回购股份23.9万股，占公司现有已发行股本约0.0248%。本次回购每股价格介乎6.045港元至6.195港元，合共耗资1,469,885港元。本次回购完成后，公司已发行股本由原先的965,393,697股减少至965,154,697股，同时库藏股数由8,988,000股增至9,227,000股，公司总股本仍为974,381,697股。董事会指出，该股份购回授权于2026年6月12日获股东大会批准，授权购回的股份总数为96,850,669股。截至目前，公司已根据该授权累计回购3,352,000股，占授权数量约0.3461%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B：11月11日回购23.9万股股份，涉资约146.99万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682447303","title":"康宁杰瑞制药-B(09966.HK)11月11日斥资约146.99万港元回购23.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682447303","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682447303?lang=zh_cn&edition=full","pubTime":"2026-11-11 18:53","pubTimestamp":1794394396,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122565790","title":"康宁杰瑞制药-B11月6日回购312,000股股份，总额约197.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122565790","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122565790?lang=zh_cn&edition=full","pubTime":"2026-11-06 20:42","pubTimestamp":1793968928,"startTime":"0","endTime":"0","summary":"2026年11月6日，康宁杰瑞制药-B公告称，当日于香港联交所场内回购312,000股普通股，占回购前公司已发行股份总数约0.0323%。本次回购每股价格介乎每股6.22港元至6.38港元，总金额约197.21万港元。回购完成后，公司已发行股份减少至965,393,697股，库藏股增至8,988,000股，已发行股本总数仍为974,381,697股。公司于2026年6月12日通过购回授权，可回购股份总数为96,850,669股，截至本次回购完成后，已累计回购3,113,000股。公司表示，本次回购符合香港联交所相关上市规则及其他适用法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B11月6日回购312,000股股份，总额约197.21万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681686639","title":"康宁杰瑞制药-B(09966)11月6日斥资约197.21万港元回购31.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681686639","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681686639?lang=zh_cn&edition=full","pubTime":"2026-11-06 20:28","pubTimestamp":1793968117,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年11月6日该公司斥资约197.21万港元回购31.2万股，回购价格为每股6.22至6.38港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681026189","title":"康宁杰瑞制药-B(09966)11月5日斥资36.7万港元回购5.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681026189","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681026189?lang=zh_cn&edition=full","pubTime":"2026-11-05 19:14","pubTimestamp":1793877296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年11月5日斥资36.7万港元回购5.6万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150293238","title":"康宁杰瑞制药-B回购5.6万股股份，耗资约36.70万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150293238","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150293238?lang=zh_cn&edition=full","pubTime":"2026-11-05 19:11","pubTimestamp":1793877108,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年11月5日发布翌日报表，公告显示公司于当日通过香港联交所场内回购普通股合计56,000股，占回购前已发行股本约0.0058%。最高每股回购价为6.60港元，最低回购价为6.39港元，合计耗资约36.70万港元。\n本次回购完成后，公司于当日的已发行股本（不包括库藏股）降至965,705,697股，库藏股数量增至8,676,000股。公告同时披露，公司回购授权于2026年6月12日通过，可回购股数上限为96,850,669股，至今公司已合计回购股份2,801,000股。\n公司确认相关回购行为符合香港联交所证券上市规则及相关法律法规。本次公告由公司执行董事徐霆签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B回购5.6万股股份，耗资约36.70万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117883561","title":"康宁杰瑞制药-B10月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117883561","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117883561?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:15","pubTimestamp":1793870140,"startTime":"0","endTime":"0","summary":"2026年11月5日，康宁杰瑞制药-B披露截至2026年10月31日的股份变动月报。报告显示，公司10月底法定股本与前一个月相比未发生变化，授权/注册股本总额仍为25,100,000,000股普通股，面值每股USD 0.000002，合计USD 50,200。公司已发行股份方面，10月初至月末保持总股本974,381,697股不变。综上，截至10月底，公司总股本维持不变。公告由公司执行董事徐霆签署。公司表示将继续严格遵守香港联交所《上市规则》及其他法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162906139","title":"康宁杰瑞制药-B 11月3日回购16万股，耗资约97.75万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162906139","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162906139?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:55","pubTimestamp":1793710546,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年11月3日在香港联交所场内回购普通股160,000股，占回购前公司已发行股份约0.0166%。每股回购价格介乎6.055港元至6.18港元不等，合计支付约97.75万港元。回购完成后，公司不含库藏股的已发行股份总数降至965,761,697股，库藏股数量增至8,620,000股，合并计算公司已发行股份总数仍为974,381,697股。公司确认本次回购已符合香港联交所《主板上市规则》等相关规定。公告由执行董事徐霆签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康宁杰瑞制药-B 11月3日回购16万股，耗资约97.75万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680729956","title":"康宁杰瑞制药-B(09966)11月3日斥资97.75万港元回购16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680729956","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680729956?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:49","pubTimestamp":1793710148,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年11月3日斥资97.75万港元回购16万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680299597","title":"康宁杰瑞制药-B(09966.HK)11月3日斥资97.75万港元回购16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680299597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680299597?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:49","pubTimestamp":1793710148,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169997625","title":"康宁杰瑞制药-B11月2日回购23万股，耗资约139.41万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169997625","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169997625?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:51","pubTimestamp":1793620269,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年11月2日公告称，公司在香港联交所场内回购230,000股股份，约占回购前公司已发行股本的0.0238%。根据公告，回购价格介乎每股5.985港元至6.12港元，总成交金额为1,394,105港元，折合约139.41万港元。回购授权于2026年6月12日获得股东大会通过，总回购额度为96,850,669股。截至本次回购，已购回2,585,000股，占授权通过当日公司已发行股份总数约0.2669%。公司同时确认已遵守香港联交所证券上市规则及相关适用法律法规。本次公告由公司执行董事徐霆签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康宁杰瑞制药-B11月2日回购23万股，耗资约139.41万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680759057","title":"康宁杰瑞制药-B(09966)11月2日斥资约139.41万港元回购23万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680759057","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680759057?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:47","pubTimestamp":1793620025,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年11月2日该公司斥资约139.41万港元回购23万股，回购价格为每股5.985至6.12港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680787814","title":"康宁杰瑞制药-B(09966)：JSKN021 I期临床研究的IND获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680787814","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680787814?lang=zh_cn&edition=full","pubTime":"2026-11-02 12:04","pubTimestamp":1793592246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，美国食品药品监督管理局已批准JSKN021进行 I期临床研究的新药临床试验申请，标志着JSKN021的海外临床开发正式启动。JSKN021-101是一项开放、多中心I期临床研究，拟纳入经标准治疗后复发或难治、或无获批疗法的局部晚期或转移性实体瘤患者，以评估JSKN021的安全性、耐受性、药代动力学特征及初步抗肿瘤活性。临床前研究显示，JSKN021的肿瘤抑制效果显著优于单载荷ADC并具有良好的耐受性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LABU","BK1574","BK4585","BK4588","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","LU0708995583.HKD","LU0588546209.SGD","600030","06078","LU0348825331.USD","LU0708995153.HKD","06821","LU0455707207.USD","LU1226287529.USD","06160","LU1969619763.USD","02269","09926","02268","03692","02273","01177","LU0607220059.USD","KURE","09996","LU0823426480.USD","LU0828237510.HKD","01951","LU2488822045.USD","00013","01952","06990","LU0979878070.USD","159938","01548","02096","IE00B031HY20.USD","01801","LU0039217434.USD","01530","01276","LU1794554557.SGD","LU0348766576.USD","03759","02596","02162","LU1064131003.USD","01093","06030","06996","09939","HK0000320264.USD","BK0028","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144959626","title":"康宁杰瑞制药-B补充披露Pathos AI认股权证交易信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1144959626","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144959626?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:45","pubTimestamp":1793263534,"startTime":"0","endTime":"0","summary":"2026年10月29日，康宁杰瑞制药-B（09966）发布补充公告，就2026年10月23日有关行使认股权证认购Pathos AI, Inc.优先股的公告作出进一步说明。公司董事会确认，Pathos AI 的最终实益拥有人为其创办人兼主席 Eric Paul Lefkofsky 先生。除该补充信息外，原公告其他内容保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110059169","title":"康宁杰瑞制药-B（09966）JSKN033治疗宫颈癌Ⅲ期临床试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1110059169","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110059169?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:01","pubTimestamp":1793192494,"startTime":"0","endTime":"0","summary":"2026年10月28日，康宁杰瑞制药-B发布自愿公告称，其自主开发的高浓度皮下注射复方制剂JSKN033已在Ⅲ期临床研究中完成首例患者给药。\\n\\nJSKN033由HER2双特异性ADC和PD-L1单域抗体组成，是目前全球首个进入注册临床阶段的皮下注射ADC复方制剂。\\n\\n康宁杰瑞制药-B提醒投资者，依据香港联交所证券上市规则第18A.05条，公司无法保证JSKN033能够成功开发或最终获批上市，股东及潜在投资者买卖公司股份时需审慎行事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678936804","title":"康宁杰瑞制药-B(09966.HK)：JSKN033单药治疗宫颈癌的III期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2678936804","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678936804?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:58","pubTimestamp":1793192287,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":-0.0604},{"period":"1month","weight":-0.1435},{"period":"3month","weight":-0.2722},{"period":"6month","weight":-0.3105},{"period":"1year","weight":-0.3634},{"period":"ytd","weight":-0.3724}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.0634},{"period":"1year","weight":-0.0892},{"period":"ytd","weight":-0.0513}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司的内部管线由处于不同研发阶段的抗体偶联药物（ADC）、单克隆抗体及双特异性抗体肿瘤药物组成。该公司的产品管线包括KN046（PD-L1/CTLA-4双特异性抗体）、KN026（抗HER2双特异性抗体）、KN035（皮下注射PD-L1）、JSKN003（HER2双表位ADC）、JSKN016（HER3/TROP2双特异性抗体ADC）、JSKN033（JSKN003和KN035 的皮下复方制剂）等，用于1L sq NSCLC、1L HER2+乳腺癌、1L胆道癌、晚期实体瘤、HER2表达实体瘤等适应症。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.117313},{"month":2,"riseRate":0.571429,"avgChangeRate":0.192959},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.039472},{"month":4,"riseRate":0.857143,"avgChangeRate":0.098183},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.031094},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.059361},{"month":7,"riseRate":0.428571,"avgChangeRate":0.061567},{"month":8,"riseRate":0.428571,"avgChangeRate":0.047929},{"month":9,"riseRate":0.285714,"avgChangeRate":0.127495},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.063839},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034966},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}